The AI Funding Divide: Why VCs Will Miss the Next Healthcare Category Kings (And Where CEOs Should Look Instead)

From how deals get sourced to how capital allocators think, generative AI is reshaping how venture capital works. For many, it’s seen as a positive, and there are truly great qualities that save real time and have a true operational impact. But there’s one structural problem most life sciences CEOs building novel products haven’t recognized yet. 

Large Language Models (LLM) agents are now the default screening layer at VC firms. They support day-to-day functions and act as a “first line of defense,” parsing through thousands of startup decks and clustering companies into investment categories. The work that once required an analyst team happens almost instantly.

While that sounds like progress, the danger for firms is that AI-driven screening doesn’t create new insight, it amplifies existing bias. It rewards what looks familiar and penalizes anything that requires the market to think differently. LLM-based filters become their own lens, and differentiation is lost.

So while AI makes VC faster, it’s not necessarily wiser (at least yet — I won’t rule anything out). In healthcare, where breakthroughs rarely resemble anything the market has seen before, that distinction is everything.

I call this the “AI Funding Divide.” It’s the theory that novel categories get systematically overlooked because clustering algorithms are built to surface what fits a known pattern, which means what doesn’t fit isn’t flagged for further review. It simply becomes invisible. 

But here’s the unintended consequence: The companies most capable of redefining the standard of care are the ones least likely to pass AI-driven screening.

What this means for CEOs with novel products

If you’re building something the market hasn’t seen before, the AI Funding Divide changes your ability to fundraise for reasons that have nothing to do with the quality of your science or innovative technology.

When your product is genuinely novel, you run the risk of looking like noise to these pattern-matching tools, but that’s a structural problem between how AI reads risk and how healthcare innovations are actually adopted. What that means is products capable of changing the standard of care will look uncertain to a system trained on what already exists.

The temporary solution may be to reshape your story to fit the machine or attempt to retrain better models as they release, but doing that removes the originality at the heart of your innovation. Your story becomes a rearranged version of someone else’s, and that’s not beneficial to how you differentiate yourself as a company.

This is fundamentally a capital strategy problem. What you don’t want is your product getting in the hands of the wrong investors, and consequentially, the market never gets the chance to adopt what you’ve built.

Where machines can’t go

AI outpaces humans in many remarkable ways, including making sense of data, but what falls outside that capability may dim the spotlight on important innovative categories. 

For example, AI currently cannot:

• Detect opportunities with no precedent
• Interpret behavior change across clinicians and payers
• Model the multi-stakeholder dynamics that determine whether a hospital system actually changes protocol 
• Anticipate how an entire market shifts in response to a new paradigm

Adoption cycles in healthcare are notoriously long, exhausting, emotional and dependent on cross-industry support, and these aren’t things LLMs are necessarily privy to.

In essence, the kind of market creation that rewrites the standard of care will always require human judgment.

The structural edge of patient capital

While the AI Funding Divide is running its course, family offices and sovereign wealth funds are quietly stepping into the void. That’s because their structural advantages happen to align with how healthcare innovation actually works.

Unlike traditional VCs, these investors operate without a fund clock. They also typically invest across all the “layers” needed within the healthcare economy that makes adoption of that innovation happen. Those layers typically include companies in the devices, diagnostics, data and platforms industries, creating an interconnected ecosystem. While they may use AI to scan the landscape, they still use human judgment, which is the biggest differentiator.

For sovereign wealth funds, they’re playing an even longer game with more resources, and sectors like life sciences become a way to diversify national wealth and expand investment reach around the globe.

The successful funds will use a strategic mix of AI and experienced leaders to make investment decisions, with a human eye as the final review for the decision. Those will be the winners in this new era.

Conclusion

It’s unrealistic to say that AI shouldn’t be part of the process. The initial screening is helpful, and many firms and funds have already adopted this as a baseline. However, you don’t want AI to make the final decisions for you. That should be left to an experienced leader because human instinct is more likely to recognize new breakthrough categories.

For CEOs who are building novel products, the investors you should look at are those who pair these tools with senior human expertise. It’s an important distinction that helps you get the right investment to bring your product (and potentially new category) to market. The story you tell when you are funded is your destiny. If you attract investors who are strategically aligned with the masses, it will be hard for you to break out of the noisy pack. Whether it meets your vision or not, investors set your trajectory.

As the AI Funding Divide is widening, which side of it you land on may well determine whether your category ever gets the chance to exist.

Photo: phive2015, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.